AI Article Synopsis

Article Abstract

Purpose: We evaluated the outcome of repeat transurethral bladder tumor resection for high risk nonmuscle invasive bladder cancer before induction and maintenance bacillus Calmette-Guerin.

Materials And Methods: Included in the study were 151 consecutive patients with a mean age of 68.6 years (range 32 to 86) with primary high grade, nonmuscle invasive (Ta, T1 or CIS) bladder cancer. All patients underwent repeat transurethral bladder tumor resection and were shown by repeat resection to be tumor-free or have residual tumor before bacillus Calmette-Guerin. The bacillus Calmette-Guerin response was evaluated by disease recurrence and progression.

Results: A total of 70 tumor-free patients and 47 with residual tumor received bacillus Calmette-Guerin induction and maintenance therapy after repeat transurethral bladder tumor resection, of whom 84 (71.8%) were disease-free during followup. In the tumor-free group 11.4% of tumors recurred compared with 27.7% in the residual tumor group (p <0.05). Progression was noted in 5.7% of tumor-free cases vs 17.0% of residual tumor cases (p <0.05). Time to recurrence was significantly less in the residual tumor group than in the tumor-free group (17.8 vs 23.9 months, p <0.001).

Conclusions: Tumor-free status at repeat transurethral bladder tumor resection improves the bacillus Calmette-Guerin response rate and delays tumor recurrence. During followup recurrence in residual tumor-free patients develop more likely as low grade lesions than in patients with residual tumor at repeat transurethral bladder tumor resection.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2010.02.026DOI Listing

Publication Analysis

Top Keywords

bacillus calmette-guerin
16
bladder cancer
12
repeat transurethral
12
transurethral bladder
12
bladder tumor
12
tumor resection
12
residual tumor
12
repeat resection
8
high grade
8
cis bladder
8

Similar Publications

Tuberculosis (TB) remains a highly lethal infectious disease. The primary preventive measure is Bacille Calmette-Guérin (BCG), a live attenuated vaccine. However, the current intradermal vaccination method with 10-dose vials faces challenges such as inadequate infant injection, inaccurate dispensing, and unstable storage.

View Article and Find Full Text PDF

Southeast Asia (SEA) countries are characterised by a high burden of tuberculosis (TB). This research seeks to compile evidence of the prevalence and risk factors associated with TB among children in SEA countries. The searching of articles was conducted for four databases (PubMed, Scopus, Embase, and the Web of Science) published between 2013 and 2023 in the English language.

View Article and Find Full Text PDF

Bladder cancer remains a significant global health concern, being the 10th most common malignancy worldwide and the 6th most common neoplasia in males, with alarming annual incidence and mortality rates. The current narrative review was planned to delve into the multifaceted landscape of bladder cancer, exploring its epidemiology, risk factors and diagnostic modalities. While white light cystoscopy has long been considered the gold standard for bladder cancer diagnosis and surveillance, the emergence of blue light cystoscopy has ushered in a new era of early detection.

View Article and Find Full Text PDF

Update of diagnostic methods in tuberculosis (TB).

Rev Argent Microbiol

January 2025

Servicio de Microbiología, Universidad Católica de Córdoba, Clínica Universitaria Reina Fabiola, Córdoba, Argentina. Electronic address:

The WHO aims to reduce the number of deaths from TB by 95% and decrease its incidence rate by 90% between 2015 and 2035. The recommended rapid diagnostic tests are accurate and cost-effective, allow for a prompt start to treatment, and influence other outcomes that are important to the patient. To detect latent infection, the tuberculin skin test and interferon γ release (IGRA) tests are used.

View Article and Find Full Text PDF

For patients with high-risk non-muscle-invasive bladder cancer (NMIBC) for whom bacillus Calmette-Guérin (BCG) treatment has failed, bladder preservation is a high priority. Immune checkpoint inhibitors have shown promise, but systemic administration is associated with substantial toxicity. In this single-arm phase 2 study, 30 patients with NMIBC after BCG failure were treated with intravesical durvalumab every 6 wk.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!